About Elastagen
Elastagen is a Healthcare company based in Sydney (Australia) founded in 2003, and was acquired by Allergan in February 2018. Company offering solutions for cell growth and tissue repair through their Elastin technology. Elastagen has raised $14.68 million across 6 funding rounds from investors including Korea Investment Holdings, Allergan and AmorePacific. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified.
Company details
Elastagen was founded in 2003 in Sydney, Australia, as a clinical-stage medical company specializing in tropoelastin-based formulations for tissue repair and cell growth. A pipeline of products is developed using recombinant human tropoelastin, with ongoing pivotal clinical studies for an injectable dermo-aesthetic treatment aimed at restoring skin elasticity. Investigations are also conducted into applications for atrophic scars, scar revision, and wound healing. Operations extend to Europe and the UK.
- Headquarters Sydney, Australia
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website elastagen.com
- Social LinkedIn X
- Acquired by Allergan (Feb 2018)
- Total Equity Funding$14.68M (USD)
in 6 rounds
- Latest Funding Round$4M (USD), Grant
Oct 2016
- InvestorsKorea Investment Holdings
& 8 more
- Acquired byAllergan
(Feb 2018)
Funding Insights of Elastagen
Elastagen has successfully raised a total of $14.68M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $4 million completed in October 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.68M
- Total Rounds 6
- Last Round Grant β $4M
- Investors Count 8
All 6 funding rounds of Elastagen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2016 | $4M | Grant | β | β | β |
| Jun 2016 | $744,830 | Series B | β | β | |
| Jan 2016 | $9.23M | Series B | β | Wellcome Trust, AmorePacific | |
| Jul 2013 | $2M | Grant | β | β | |
| Aug 2008 | $4.7M | Series A | β | β | |
| Jun 2005 | Seed | β | β |
9 investors in total: 9 institutional.
Investors in Elastagen
Elastagen has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Korea Investment Holdings, Allergan and AmorePacific.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| gbsventures.com.au | ||||
Early-stage medical companies are funded by this venture capital firm. | brandoncapital.vc | Melbourne, Australia | ||
Investment holding firm established in Seoul in 2003. | 2003 | koreainvestment.com | Seoul, South Korea | |
| cell-ip.com | ||||
Wellcome is a global charitable foundation focused on health research. | wellcome.ac.uk | London, United Kingdom | ||
| atp-innovations.com.au | ||||
Beauty products are manufactured and exported by AmorePacific. | 1945 | amorepacific.com | Seoul, South Korea | |
NSW Health is tasked with providing public health services across New South Wales. | health.nsw.gov.au | St Leonards, Australia | ||
A portfolio of generic medicines is developed and manufactured. | 1948 | allergan.com | Madison, United States |
Investor details for Elastagen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Elastagen
4 dated milestones of Elastagen across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Elastagen is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $4.0M.
- Exit Acquired by Allergan.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Elastagen
Complete news archive for Elastagen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Elastagen
Elastagen was founded in 2003 and raised its 1st funding round 2 years after it was founded.
Elastagen is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.
Elastagen is a funded company, having raised a total of $14.68M across 6 funding rounds to date.
Elastagen was founded in 2003 in Sydney, Australia, as a clinical-stage medical company specializing in tropoelastin-based formulations for tissue repair and cell growth. A pipeline of products is developed using recombinant human tropoelastin, with ongoing pivotal clinical studies for an injectable dermo-aesthetic treatment aimed at restoring skin elasticity. Investigations are also conducted into applications for atrophic scars, scar revision, and wound healing. Operations extend to Europe and the UK.
Elastagen has 9 investors. Key investors include Korea Investment Holdings, Allergan, AmorePacific, Wellcome, and GBS.
Yes. Elastagen was acquired by Allergan in February 2018.

